• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Annovis Bio, Inc. Common Stock (NY:ANVS)

2.280 +0.020 (+0.88%)
Official Closing Price Updated: 7:00 PM EDT, May 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Annovis Bio, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
MissionIRNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) CEO to Present Alzheimer’s Multi-Protein Research at Fierce Biotech Week 2026
May 07, 2026
Via Investor Brand Network
News headline image
Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026
May 07, 2026
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio
April 28, 2026
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Closes $10 Million Offering To Fund Phase 3 Milestones Through 2027
April 10, 2026
Via Investor Brand Network
News headline image
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission
April 10, 2026
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants
April 09, 2026
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections
April 02, 2026
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Highlights Buntanetap Development in The Scientist Publication
March 31, 2026
Via Investor Brand Network
News headline image
Annovis Publishes Historical Review of Buntanetap in The Scientist
March 31, 2026
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Partners With NeuroRPM To Integrate AI Platform In Parkinson Study
March 19, 2026
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial
March 19, 2026
From NeuroRPM Inc.
Via GlobeNewswire
News headline image
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study
March 19, 2026
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results
March 16, 2026
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference
March 03, 2026
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Receives Positive DSMB Recommendation to Continue Phase 3 Alzheimer’s Trial
February 12, 2026
Via Investor Brand Network
News headline image
Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease
February 12, 2026
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Launch Open-Label Extension Study of Buntanetap in Parkinson Disease
December 19, 2025
Via Investor Brand Network
News headline image
Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients
December 18, 2025
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Schedules Corporate Update Webinar and Live Q&A Session
December 16, 2025
Via Investor Brand Network
News headline image
Annovis to Host Corporate Update Webinar on January 28, 2026
December 16, 2025
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Present New Buntanetap Findings at Parkinson Study Group Annual Meeting
December 03, 2025
Via Investor Brand Network
News headline image
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group
December 03, 2025
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Annovis Announces Two Presentations at the CTAD 2025 Conference
November 24, 2025
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Secures FDA Type C Meeting to Advance Parkinson’s Disease Dementia Program
November 18, 2025
Via Investor Brand Network
News headline image
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
November 18, 2025
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
November 18, 2025
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:NTLA),(NASDAQ:ZYME),(NYSE:ANVS) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study
November 18, 2025
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports New Data Showing Buntanetap Reverses Cognitive Decline in Parkinson’s Patients With Amyloid Co-Pathology
November 17, 2025
Via Investor Brand Network
News headline image
Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients
November 17, 2025
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports Major Clinical and Corporate Milestones as Phase 3 Alzheimer’s Trial Advances Toward Completion
November 12, 2025
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap